Breast cancer, endocrine therapy is a selective targeted therapy earliest successful examples of situation from the receptors, estrogen and progesterone receptor-positive patients with the best results. Line endocrine therapy for breast cancer, estrogen receptor (+) and progesterone receptor (+) were effective up to 60%, estrogen receptor (+) and progesterone receptor (-) or estrogen receptor (-) pregnant hormone receptor (+) in an efficient 20-30%, while the estrogen receptor (-) progesterone receptor (-) 5% of those effective left –
Right. Is generally believed that, for estrogen or progesterone receptor-positive patients, regardless of their age. Menstrual status. Oncology small. Lymph node has transferred shall be subject to endocrine therapy.
From the stages of treatment point of view, Furlong can be used for second-line rescue. First-line rescue. And a new secondary phase.
1. Second-line rescue. Recurrence after the transfer, used chemotherapy or other endocrine therapy, but the disease still progress in treatment failure of patients need second-line rescue. To Femara for the treatment of drug use AR/BC2 test in 10 countries, 91 hospitals completed the 551 cases of patients with the treatment of postmenopausal women with advanced, effective 23.6%, benefiting from rate was 33.3%, overall assessment of efficacy was better than sleep-amino derivative able. Another large-scale international center AR/BC3 test in 11 countries, 86 hospitals in 444 postmenopausal patients with advanced, effective 19.5%, benefiting from rate was 36.6% more effective than megestrol acetate.
2. Line rescue. Head of the most influential. The most important test is to rescue the 025 first-line test. The trial in 29 countries, 201 hospitals, 910 cases of recurrence and metastasis in patients with treatment efficiency of 30.2%, benefiting from rate was 48.8% more effective than tamoxifen, because these patients are metastasis and recurrence after a begin with the Furlong, therefore, more effective than second-line rescue the AR/BC2 and AR/BC3 test patients.
3. The new adjuvant therapy. Neo-adjuvant treatment of 024 trials in 16 countries, 55 hospitals have treated 324 cases of pre-operative patients. After treatment, these patients through clinical medical checkup, efficiency of 55%, by ultrasound and X-ray examination, efficiency of 34% -35%. These were neo-adjuvant treatment of patients, application of anti-cancer treatment Femara is the first time, that is the first time that treatment for breast cancer, so off than first-line treatment for good results to save some, the overall effect is also better than tamoxifen.
4. Strengthen the adjuvant therapy. Application of tamoxifen treatment after surgery, after five years continue to strengthen its taking Femara for five years can reduce the risk of recurrence of breast cancer 43% and 50% of contralateral breast cancer, and can significantly improve disease-free survival.
